94 related articles for article (PubMed ID: 3802028)
1. The prognostic importance of myelosuppression in the response to chemotherapy and survival in advanced ovarian carcinoma.
Sorbe B; Helsing M
Cancer; 1987 Feb; 59(4):690-4. PubMed ID: 3802028
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group.
Tropé C; Andersson H; Björkholm E; Frankendal B; Himmelman A; Högberg T; Horvath G; Petterson B; Persson H; Ryberg M; Simonsen E; Sorbe B; Stendahl U; Westholm B
Acta Oncol; 1996; 35 Suppl 8():109-18. PubMed ID: 9073056
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
[TBL] [Abstract][Full Text] [Related]
7. Advanced ovarian carcinoma. Factors influencing survival.
Klein B; Falkson G; Smit CF
Cancer; 1985 Apr; 55(8):1829-34. PubMed ID: 3978568
[TBL] [Abstract][Full Text] [Related]
8. Melphalan with and without doxorubicin in advanced ovarian cancer.
Tropé C
Obstet Gynecol; 1987 Oct; 70(4):582-6. PubMed ID: 3306509
[TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second look laparotomy in patients with chemosensitive advanced ovarian carcinoma: long-term results.
Bertucci F; Viens P; Delpero JR; Bardou VJ; Faucher C; Houvenaeghel G; Maraninchi D
Bone Marrow Transplant; 2000 Jul; 26(1):61-7. PubMed ID: 10918406
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
Omura GA; Brady MF; Homesley HD; Yordan E; Major FJ; Buchsbaum HJ; Park RC
J Clin Oncol; 1991 Jul; 9(7):1138-50. PubMed ID: 1904477
[TBL] [Abstract][Full Text] [Related]
11. Melphalan chemotherapy in advanced ovarian carcinoma.
Piver MS; Barlow JJ; Yazigi R; Blumenson LE
Obstet Gynecol; 1978 Mar; 51(3):352-6. PubMed ID: 628541
[TBL] [Abstract][Full Text] [Related]
12. Peptichemio in pretreated patients with ovarian cancer.
Paccagnella A; Tredese F; Salvagno L; Brandes A; Sileni VC; Daniele O; Fornasiero A; Fosser V; Nicoletto O; Maggino T
Cancer Treat Rep; 1985 Jan; 69(1):17-20. PubMed ID: 3155650
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
Neijt JP; ten Bokkel Huinink WW; van der Burg ME; van Oosterom AT; Willemse PH; Heintz AP; van Lent M; Trimbos JB; Bouma J; Vermorken JB
J Clin Oncol; 1987 Aug; 5(8):1157-68. PubMed ID: 3114434
[TBL] [Abstract][Full Text] [Related]
14. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer.
Tas F; Yildiz I; Kilic L; Ciftci R; Keskin S; Sen F
Am J Ther; 2016; 23(3):e670-9. PubMed ID: 23782755
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of advanced epithelial ovarian carcinoma].
Meerpohl HG
Onkologie; 1984 May; 7 Suppl 2():22-34. PubMed ID: 6431349
[TBL] [Abstract][Full Text] [Related]
17. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA
J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
[TBL] [Abstract][Full Text] [Related]
18. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
19. I.v. melphalan in carcinoma of the lung: effect of cyclophosphamide priming on hematopoietic toxicity.
Spitzer G; Valdivieso M; Farha P; Murphy WK; Dhingra HM; Chiuten D; Umsawasdi T; Holoye P
Cancer Treat Rep; 1986 Apr; 70(4):449-53. PubMed ID: 3698037
[TBL] [Abstract][Full Text] [Related]
20. High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Thatcher D; Lind M; Morgenstern G; Carr T; Chadwick G; Jones R; Craig P
Cancer; 1989 Apr; 63(7):1296-302. PubMed ID: 2646005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]